middle.news
How Cyclopharm’s Technegas® Is Revolutionizing U.S. Lung Imaging Markets
1:13am on Saturday 30th of August, 2025 AEST
•
Healthcare
Read Story
How Cyclopharm’s Technegas® Is Revolutionizing U.S. Lung Imaging Markets
1:13am on Saturday 30th of August, 2025 AEST
Key Points
Record half-year revenue of $15.42 million, up 26%
U.S. Technegas® installations doubled to 35 with $1.24 million revenue
Third-party distribution revenue surged 58%, now half of total sales
U.S. patent exclusivity extended to 2031 with new IP filings for 20-year runway
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Cyclopharm (ASX:CYC)
OPEN ARTICLE